SironRX Therapeutics
Cleveland
About SironRX Therapeutics
SironRX is developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote dermal wound repair and reduce scarring. Our lead product is a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1). SDF-1 is key molecule responsible for activating natural repair processes after tissue injury through prevention of cell death and recruitment of stem cells to the damaged organ. Studies from several laboratories suggest the therapeutic potential of SDF-1 for treatment of a range of wounds such as post-surgical incisions, chronic diabetic ulcers and burns. Development of a cost-effective interactive wound therapy that can be topically administered at the site-of-injury or in chronic wound care settings with the potential to significantly improve function of the damaged tissue will have a major impact on the multi-billion dollar advanced wound management market.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $3.9M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2011)
- Website: sironrx.com
- Phone: +1 216-445-0830
Industries & Categories
Biotechnology, Medical, Therapeutics
Canonical: https://fsome.com/organization/sironrx-therapeutics-2951666 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.